arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Mosaic ImmunoEngineering Inc.

CPMV
— Price unavailable
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
17 Visible periods
20 Metrics
Peer-ranked Benchmarks
Price Chart
41
Health
Weak
Neutral
auto_awesome

Analytical Summary

Mosaic ImmunoEngineering Inc. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap —
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC 8.3% ↘
FCF / Share $-0.02 ↗
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close.

17-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-687.85K
↑ +25.4% —
FCF / Share Free cash flow per share
$-0.02
↑ +53.8% —

Health Breakdown

Returns ↓
65
Financial Health ↑
16
Cash Quality ↓
28

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 17 years · 67 quarters